论文部分内容阅读
目的研究肠型胃癌中HDAC1与Oct4表达的关系。方法采用免疫组化方法检测临床资料完整的661例肠型胃癌及其对应癌旁正常胃组织标本中HDAC1与Oct4的表达,结合临床病理资料对实验结果进行统计分析;生存分析研究其预后价值。结果 Oct4的阳性表达与肿瘤大小、区域淋巴结转移、细胞分化、HDAC1表达(P<0.001)、浸润深度(P=0.003)均显著相关;在Oct4阳性表达和阴性表达的组织标本中,HDAC1的高表达率分别是66.0%和34.0%,两者呈正相关(P<0.001);生存分析显示:Oct4阴性表达患者的总生存显著高于Oct4阳性表达患者(P<0.001),Oct4阴性/HDAC1低表达患者的总生存显著高于其他组合(P<0.001)。结论肠型胃癌中,Oct4与HDAC1的表达呈正相关,采用Oct4和HDAC1双靶向抑制治疗可能有更长的总生存。
Objective To study the relationship between HDAC1 and Oct4 expression in intestinal-type gastric cancer. Methods Immunohistochemical method was used to detect the expression of HDAC1 and Oct4 in 661 cases of intestinal type gastric cancer and their adjacent normal gastric tissues with clinical data. The clinical data were used to analyze the experimental results and the prognostic value of survival was analyzed. Results The positive expression of Oct4 was significantly correlated with tumor size, regional lymph node metastasis, cell differentiation, HDAC1 expression (P <0.001) and depth of invasion (P = 0.003). In Oct4 positive and negative tissues, the expression of HDAC1 The overall survival was significantly higher in patients with Oct4-negative expression than in those with Oct4-positive expression (P <0.001), while the expression of Oct4-negative / HDAC1 was low (P <0.001) Patients had significantly higher overall survival than the other groups (P <0.001). Conclusion The expression of Oct4 and HDAC1 in intestinal-type gastric cancer is positively correlated. Oct4 and HDAC1 dual-targeted inhibition therapy may have longer overall survival.